*University of Texas MD Anderson Cancer Center, Houston, TX
†American Society of Clinical Oncology, Stanford Cancer Center, Stanford, CA
‡Princess Margaret Hospital, Toronto, Ontario, Canada
§University of Rochester Medical Center
‡‡‡University of Rochester Medical Center, Rochester
†††American Society of Clinical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
∥American Society of Clinical Oncology, Emory University, Atlanta, GA
¶Univeristy of Texas Health Science Center at San Antonio, San Antonio, TX
#University of Florida Proton Therapy Institute, Jacksonville
**University of Florida, Gainesville, FL
††American Society of Clinical Oncology, St. Jude Children’s Research Hospital, Memphis, TN
‡‡University of Pennsylvania Health System, Philadelphia, PA
§§Yale University School of Medicine, New Haven, CT
∥∥Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN
¶¶American Society of Hematology, University of Chicago, Chicago, IL
##Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD
***Massachusetts General Hospital, Boston, MA
For additional information on the Appropriateness Criteria methodology and other supporting documents go to http://www.acr.org/ac.
C.R.F.: provides consulting for the Prescription Solutions Pharmacy and Therapeutics division. Consultation involves advice on FDA Regulated drugs only. None of the consultation overlaps with existing or planned ACR guidelines. A.Y.: Honorarium from: Novartis, Seattle Genetics, Millenium, Clegene, Curis, Sanofi, Pharmacyclics, and Incyte. Research Support from: Novartis, Johnson & Johnson, Seattle Genetics, Merck, Genentech, Infinity, and Gilead. The remaining authors declare no conflicts of interest.
The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.
Correspondence: Bouthaina S. Dabaja, MD, Department of Radiation Oncology, 1515 Holcombe Blvd Unit 97, Houston, TX 77030-4000. E-mail: [email protected]. Reprints: [email protected]
